CRISPR Therapeutics ($CRSP) Insider Trading & Smart Money Activity
CRISPR Therapeutics AG ($CRSP) has 6 insider trades and 4 13F position changes on file. In the last 12 months on the open market, no insider bought and 4 insiders sold ($2.50M), net -$2.50M.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 4
- Net insider $ (12 mo)
- -$2.50M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 4
- Analyst ratings on file
- 0
CRSP insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 0 | 0 / 0 | 2 / 2 |
| Q3 2026 | 0 | 2 · $1.41M | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 4 · $1.09M | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All CRSP insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Kulkarni SamarthChief Executive Officer | Sell (Open-market sale) | 4.10K sh | $201.87K | Read | ||||||
| Insider | Kasinger James R.General Counsel and Secretary | Sell (Open-market sale) | 1.04K sh | $51.23K | Read | ||||||
| Insider | Simeon GeorgeDirector | Sell (Open-market sale) 10b5-1 | 14.51K sh | $720.37K | -48.38% | SEC | Read | ||||
| Insider | Kasinger James R.General Counsel and Secretary | Sell (Open-market sale) 10b5-1 | 1.99K sh | $119.48K | -7.2% | — | |||||
| Insider | Kasinger James R.General Counsel and Secretary | Sell (Open-market sale) 10b5-1 | 10.40K sh | $626.46K | -5.1% | — | |||||
| Insider | Behbahani AliDirector | Sell (Open-market sale) | 13.68K sh | $780.94K | -2.8% | — | |||||
| 13F | ARK Investment Management | Added | +791.57K sh | $586.50M | -9.9% | -4.9% | — | ||||
| 13F | ARK Investment Management | Added | +791.57K sh | $617.05M | -9.9% | -4.9% | — | ||||
| 13F | Dekabank Deutsche Girozentrale | Sold out | -40.74K sh | -3.8% | -1.6% | — | |||||
| 13F | Dekabank Deutsche Girozentrale | Sold out | -40.74K sh | -3.8% | -1.6% | — |
1W / 1M / 6M = how CRSP moved from the trade or filing date.
Insider trading in CRSP: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Kasinger James R. | General Counsel and Secretary | 3 | -$797.17K | Oct 14, 2026 | |
| Kulkarni Samarth | Chief Executive Officer | 1 | -$201.87K | Oct 14, 2026 | |
| Simeon George | Director | 1 | -$720.37K | 15.49K | Oct 14, 2026 |
| Behbahani Ali | Director | 1 | -$780.94K | Sep 17, 2026 |
Institutions moving CRSP (13F)
Frequently asked questions
Are CRSP insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 4 insiders made 6 open-market sales worth $2.50M, a net -$2.50M.
What is the latest insider trade in CRSP?
Kulkarni Samarth, Chief Executive Officer filed a sell (open-market sale) of 4.10K sh worth $201.87K on Oct 14, 2026.
Which institutions changed their CRSP positions?
Recent 13F filers moving the stock include ARK Investment Management and Dekabank Deutsche Girozentrale.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.